Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Broader shield: can a 20-Valent vaccine outsmart pneumonia in babies?

NCT ID NCT07754539

Vaccine Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This trial evaluates an experimental vaccine called 20vPnC, designed to protect against 20 types of pneumococcal bacteria. Healthy infants aged 42 to 98 days will receive either 20vPnC or the approved 13vPnC vaccine at 2, 4, 6, and 12-15 months. The study aims to compare safety and immune responses between the two vaccines.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
20-valent pneumococcal conjugate vaccine (20vPnC)
What this could lead to
If successful, this vaccine could offer broader protection against pneumococcal infections in infants, potentially reducing disease burden.
What could go wrong
The trial is in Phase 3 but results may not confirm superior efficacy or safety. Possible side effects include local reactions and systemic events.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 1,250 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

May 2031

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

42 to 98 days

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: \- Healthy male or female infants born at ≥37 weeks of gestation and who are approximately 2 months of age (≥42 to ≤98 days) at the time of consent (the day of birth is considered Day 1 of life) will be enrolled. Key Exclusion Criteria: * history of a severe adverse reaction associated with a vaccine and/or severe allergic reactions to any component of the study intervention. * significant neurological disorder or history of seizure or significant stable or evolving disorders. * major known congenital malformation or serious chronic disorder. * history of microbiologically proven invasive disease caused by S. pneumoniae. * known or suspected immunodeficiency or other conditions associated with immunosuppression. * previous vaccination with any licensed or investigational pneumococcal vaccine or planned receipt through study participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pneumococcal diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pneumococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pneumococcal diseases

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention

    RECRUITING

    Nanning, Guangxi, 530021, China

  • Hezhou Center for Disease Control and Prevention

    RECRUITING

    Hezhou, Guangxi, 542800, China

  • Wuming District Center for Disease Control and Prevention

    RECRUITING

    Nanning, Guangxi, 530199, China

  • Zhongshan County Center for Disease Control and Prevention

    RECRUITING

    Zhongshan Town, Guangxi, 542600, China